Filter By Category
Archives
Share on -
DUTOGLIPTIN
Generic Name: DUTOGLIPTIN
ABSTRACT -
Dutogliptin is an investigational small-molecule dipeptidyl peptidase-4 inhibitor studied for type 2 diabetes and other cardiometabolic research settings.
DOSAGE -
No approved dosage. Clinical trials have evaluated oral once-daily regimens such as 200-400 mg depending on study design.
SIDE EEFECTS -
- Headache
- Nasopharyngitis or upper respiratory symptoms
- Dizziness
- Arthralgia
- Gastrointestinal symptoms
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or pruritus
- Urticaria
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Insulin or sulfonylureas may increase hypoglycemia risk
- Other DPP-4 inhibitors should not be combined
- Renally cleared medicines may require renal-function monitoring
PREAUTONS–
- Monitor blood glucose and HbA1c in diabetes studies
- Assess renal function
- Watch for pancreatitis symptoms
WARNINGS –
- Investigational; not approved for routine treatment
- Potential pancreatitis and serious hypersensitivity class concerns
Share on -
. Developed by